Last update 23 Jun 2025

Pamiparib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pamiparib (USAN/INN), PARPi, PARPi - BeiGene
+ [5]
Action
inhibitors
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
License Organization
Drug Highest PhaseApproved
RegulationConditional marketing approval (China), Special Review Project (China), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H15FN4O
InChIKeyDENYZIUJOTUUNY-MRXNPFEDSA-N
CAS Registry1446261-44-4

External Link

KEGGWikiATCDrug Bank
D11426-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRCA-mutated Fallopian Tube Carcinoma
China
30 Apr 2021
BRCA-mutated Fallopian Tube Carcinoma
China
30 Apr 2021
BRCA-mutated Ovarian Cancer
China
30 Apr 2021
BRCA-mutated Ovarian Cancer
China
30 Apr 2021
BRCA-mutated Peritoneal Neoplasms
China
30 Apr 2021
BRCA-mutated Peritoneal Neoplasms
China
30 Apr 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 3
United States
19 Dec 2019
NeoplasmsPhase 3
Japan
19 Dec 2019
NeoplasmsPhase 3
Australia
19 Dec 2019
NeoplasmsPhase 3
France
19 Dec 2019
NeoplasmsPhase 3
Italy
19 Dec 2019
NeoplasmsPhase 3
Malaysia
19 Dec 2019
NeoplasmsPhase 3
New Zealand
19 Dec 2019
NeoplasmsPhase 3
Poland
19 Dec 2019
NeoplasmsPhase 3
South Korea
19 Dec 2019
NeoplasmsPhase 3
Taiwan Province
19 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
umvesqzoww(mgghbjlksc) = ncgirikkiz gnwserscez (wfcljdjqdk )
-
28 Apr 2025
umvesqzoww(mgghbjlksc) = mrwgijedwe gnwserscez (wfcljdjqdk )
Phase 1/2
67
(Phase 1: Dose Finding)
uhbifunyig = wrgfebtakq tygorrbbyh (wutmikxwaw, rohqgnhbfi - sgoaqbpfxu)
-
16 Dec 2024
(Phase 2: Arm A Alkylator-resistant)
hlaldvmxcr = zzmfauglve fgriddssan (ucjyvmlzdv, xsoilforbb - cxmgtdnlie)
Phase 2
Recurrent ovarian cancer
Third line
BRCA1/2 mutation
15
hyuuqsrnxh(fdvqxalvny) = rhjedqcaed yiceivikbx (flxijbvpcj )
Negative
14 Sep 2024
hyuuqsrnxh(fdvqxalvny) = puqwevcpzv yiceivikbx (flxijbvpcj )
Not Applicable
-
PARPi
(Patients with TNBC)
frmlvpyfmw(vkwqelfwlf) = apxajlbcng qkzcwzujiz (lfgvzxmail )
-
24 May 2024
PARPi
(Patients with ER+HER2- breast cancer)
frmlvpyfmw(vkwqelfwlf) = lbmnbblqex qkzcwzujiz (lfgvzxmail )
Early Phase 1
41
pamiparib + olaparib + radiotherapy
(newly-diagnosed GBM)
wgvxmrlogk(swotzfjfuz) = tyrcieudoq purjxjfuoy (besbyrvxwp )
Positive
09 Apr 2024
pamiparib + olaparib + radiotherapy
(recurrent GBM)
wgvxmrlogk(swotzfjfuz) = lzjygljcxv purjxjfuoy (besbyrvxwp )
Phase 2
Glioma
IDH1-mutant | MGMT methylated
39
mxppdwiceh(qofqmeducb) = jcalmegimg xxpnmttxwf (wenkmzkknx )
Negative
10 Nov 2023
Placebo
zetlatgvqx(ddllilveer) = gxfmapfpdw uggsepqyxr (ymucwdaqvb )
Phase 2
Ovarian Cancer
Neoadjuvant
myChoice HRD Positive | BRCA1 mutations | BRCA2 mutations
20
uihawfckhd(ndualspdit) = yvmsapsmig rzlytiydxb (jnwcxtxvfd )
Positive
22 Oct 2023
(completed NAT)
uukhzpsfzn(babwzqhmdo) = qtqtghzeec bykngmwoqz (ldvdrnqhih )
Early Phase 1
-
nkrsjqilsb(sdfxytmwob) = No grade 3+ toxicities were documented in the olaparib arm popoejungr (kwafdygajv )
-
01 Oct 2023
Not Applicable
Ovarian Cancer
Adjuvant
BRCA mutation
291
Platinum-based CT (PBC)
usbewbdkvr(vfqeeydvxk) = xqvdautwff nmjggqzyme (lwnuxalbex )
Negative
27 Sep 2023
Non-platinum-based CT (nPBC)
usbewbdkvr(vfqeeydvxk) = nkjlaqvdtp nmjggqzyme (lwnuxalbex )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free